[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356411-105":59,"doc-detail-356411-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","mir-340-improves-the-efficiency-of-p53-gene-therapy-in-metastatic-prostate-cancer-cells-through-downregulation-of-mdm2","miR-340 improves the efficiency of p53 gene therapy in metastatic prostate cancer cells through downregulation of MDM2","","Despite standard chemotherapy, radiotherapy, and hormone therapy, metastatic castration-resistant prostate cancer maintains an approximately 50% five-year survival rate, limiting the clinical impact of p53 gene therapy. This study tests whether miR-340–mediated MDM2 downregulation can enhance p53 gene therapy in p53 non-expressing PC3 cells. Lentiviral vectors generate scramble, miR-340, p53, and co-expressing cells. qPCR and protein analyses quantify MDM2 and p53-pathway changes, while proliferation, migration, apoptosis, and angiogenic assays evaluate therapeutic effects. Combined miR-340/p53 treatment increases p21 and strengthens responses to radiotherapy and low-dose docetaxel, without markedly altering apoptosis.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/mir-340-improves-the-efficiency-of-p53-gene-therapy-in-metastatic-prostate-cancer-cells-through-downregulation-of-mdm2/356411/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/mir-340-improves-the-efficiency-of-p53-gene-therapy-in-metastatic-prostate-cancer-cells-through-downregulation-of-mdm2/356411.png","ImageObject",300,407,{"name":92,"@type":93},"Theodore","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem limits p53 gene therapy in metastatic castration-resistant prostate cancer?","Question",{"text":112,"@type":113},"Tumor evasion mechanisms, especially upregulation of p53 negative regulators like MDM2, reduce the effectiveness of exogenous p53.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was miR-340 used in the experimental system?",{"text":117,"@type":113},"Lentiviral vectors were used to create PC3 cells that overexpress miR-340 alone, p53 alone, or both miR-340 and p53, along with a scramble control.",{"name":119,"@type":110,"acceptedAnswer":120},"What therapeutic improvements were observed with miR-340/p53 co-expression?",{"text":121,"@type":113},"Co-expression significantly increased p21 mRNA and p53 protein expression, inhibited proliferation and migration, reduced angiogenic potential, and enhanced responses to radiotherapy and low-dose docetaxel.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},356411,1790170099,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nmiR-340 improves the efficiency of p53 gene therapy in metastatic prostate cancer cells through downregulation of MDM2  \nRoham Deyhimfar1,2, Mousa Kehtari1, Fatemeh Saadatpour3, Alireza Nikoofar4, Ramin Heshmat5, Hamid Arshadi6, Hossein Dialameh2, EhsanArefian1,7􀀍 & Seyed Mohammad Kazem Aghamir2􀀍  \nDespite current standard treatments such as chemotherapy, radiotherapy, and hormone therapy, the five-year survival rate for patients with metastatic castration-resistant prostate cancer (mCRPC) remains about 50%. While p53 gene therapy has been widely investigated in cancer research, its clinical efficacy is limited by tumor evasion mechanisms, including the upregulation of p53 negative regulators, such as MDM2. This study aims to evaluate the impact of miR-340-mediated downregulation of MDM2 on the therapeutic efficacy of p53 gene therapy in p53 non-expressing PC3 cells. Lentiviral vectors, produced using HEK293T cells, were employed to generate scramble, miR-340-overexpressing, p53-overexpressing, and co-overexpressing PC3 cells. Quantitative polymerase chain reaction (qPCR) was used to determine the expression of p53, MDM2, p21, VEGF, and miR-340 . Cell viability, apoptosis, necrosis, cell cycle alterations, cellular migration, proliferation in 2D/3D culture, and HUVECs’ angiogenic potential were assessed in vitro. Additionally, the efficacy of radiotherapy and docetaxel chemotherapy was evaluated through MTT, flow cytometry, and colony formation assay. miR-340 reduced MDM2 mRNA expression by 66% compared to the scramble control and by 45% compared to p53-overexpressing PC3 cells. miR-340 also decreased MDM2 protein expression by 30% compared to both the scramble control and p53-overexpressing PC3 cells. In PC3 cells co-expressing miR-340 and p53, miR-340 induced a 21-fold increase in p21 mRNA levels and a 58.8% increase in p53 protein expression relative to p53-overexpressing cells. Moreover, miR-340/p53 gene therapy effectively inhibited cell proliferation, migration, and angiogenic potential of PC3 cells, without markedly affecting apoptosis rates. Interestingly, this combined gene therapy substantially enhanced the therapeutic response to radiotherapy and low-dose docetaxel chemotherapy. In conclusion, miR- 340 can enhance the efficacy of p53 gene therapy and holds promise for the management of mCRPC.  \nKeywords Prostate cancer, Gene therapy, p53, MDM2, MiR-340, Apoptosis  \nAccording to the 2022 GLOBOCAN statistics, prostate cancer ranks as the second most common malignancy in terms of incidence and the fifth most prevalent cause of cancer-related mortalities among men across the globe1. Treatment options for localized prostate cancer, such as radical prostatectomy, radiation therapy, and hormone therapy, are often associated with a favorable prognosis, as early diagnosis and timely intervention correlate strongly with a five-year survival of over 90%2. Therapeutic interventions for metastatic prostate carcinoma comprise systemic chemotherapy, androgen deprivation therapy, internal radiotherapy utilizing radium-223, and immunotherapeutic modalities such as pembrolizumab and sipuleucel-T3. Considering limited therapeutic efficacy, lack of universal applicability, development of acquired resistance, or concerning adverse effects, these  \n1Department of Stem Cells Technology and Tissue Regeneration, School of Biology, College of Science, University of Tehran, Tehran, Iran. 2Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran. 3Department of Microbiology, School of Biology, College of Science, University of Tehran, Tehran, Iran. 4Department of Radiation Oncology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. 5Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.  \n6Pediatric Urology and Regenerative Medicine R","cbCaisMMFt57qKcb","https://ap.wps.com/l/cbCaisMMFt57qKcb","pdf",7359653,16,"English","# Abstract\n## Study design and cell models\n## Molecular assessments (qPCR, protein changes)\n## Functional assays (viability, apoptosis, migration, cell cycle)\n## In vitro angiogenesis and treatment synergy","[{\"question\":\"What problem limits p53 gene therapy in metastatic castration-resistant prostate cancer?\",\"answer\":\"Tumor evasion mechanisms, especially upregulation of p53 negative regulators like MDM2, reduce the effectiveness of exogenous p53.\"},{\"question\":\"How was miR-340 used in the experimental system?\",\"answer\":\"Lentiviral vectors were used to create PC3 cells that overexpress miR-340 alone, p53 alone, or both miR-340 and p53, along with a scramble control.\"},{\"question\":\"What therapeutic improvements were observed with miR-340/p53 co-expression?\",\"answer\":\"Co-expression significantly increased p21 mRNA and p53 protein expression, inhibited proliferation and migration, reduced angiogenic potential, and enhanced responses to radiotherapy and low-dose docetaxel.\"}]","miR-340 improves the efficiency of p53 gene therapy in metastatic prostate cancer cells through downregulation of MDM2 | PDF",1790125260,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/619ee6195612dae565b532389c72e420.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/445414e44252723cac3a9995f5343c4c.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9392923ed2227dbc80b998c53215a7d0.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e4e7671821a2e12f6afff2bcf73d52f9.webp",980,1287]